EP0581797A1 - Nouveaux derives d'acide carboxylique de thiophene-2 et leur procede de preparation. - Google Patents

Nouveaux derives d'acide carboxylique de thiophene-2 et leur procede de preparation.

Info

Publication number
EP0581797A1
EP0581797A1 EP92908327A EP92908327A EP0581797A1 EP 0581797 A1 EP0581797 A1 EP 0581797A1 EP 92908327 A EP92908327 A EP 92908327A EP 92908327 A EP92908327 A EP 92908327A EP 0581797 A1 EP0581797 A1 EP 0581797A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
carboxylic acid
pharmaceutically acceptable
weak organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92908327A
Other languages
German (de)
English (en)
Other versions
EP0581797B1 (fr
Inventor
Dieter Binder
Gerhard Greier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laevosan GmbH and Co KG
Original Assignee
Laevosan GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laevosan GmbH and Co KG filed Critical Laevosan GmbH and Co KG
Publication of EP0581797A1 publication Critical patent/EP0581797A1/fr
Application granted granted Critical
Publication of EP0581797B1 publication Critical patent/EP0581797B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Definitions

  • the invention relates to novel therapeutically valuable thiophene-2-carboxylic acid derivatives and a process for their Herstel ⁇ Lung '.
  • EP-A1-0 109 381 describes a compound of the formula (I ')
  • R in position 3 or 4 is hydrogen, methyl, chlorine or bromine and R 1 is hydrogen or C_
  • the compounds according to the invention of the formula (I) given below have a strong inhibitory effect on oral thromboxane synthetase without significant inhibition of the action of prostacyclin synthetase or cyclooxygenase enzymes from platelet microsomes, ie these compounds inhibit the conversion of prostaglandin H 2 Thromboxan-B 2 via Thromboxan A 2 , which is an unstable intermediate and which, as is known, induces irreversible platelet aggregation and contracts smooth muscles, in particular those of the blood vessels.
  • the present invention thus relates to new compounds of the general formula (I)
  • R in position 3 or 4 represents hydrogen, methyl, chlorine or bromine and R 2 is C, -C, 0 alkyl, C 3 -C 7 cycloalkyl or benzyl, and their pharmaceutically acceptable addition salts with weak organic acids.
  • the absorption of the compounds according to the invention when administered orally is at least three times the absorption when the compounds are administered orally according to EP-A1-0 109 381.
  • the present invention further provides a process for the preparation of the new compounds of the formula (I) in which R and R 2 have the meanings given above, which consists in that a salt of a compound of the formula (I ")
  • X represents a leaving group suitable for nucleophilic exchange, such as halogen, preferably chlorine or bromine, and R 2 has the meaning given above, and the compound of formula (I) obtained is converted into an addition salt with a weak organic acid becomes.
  • the reaction is usually carried out by adding at least 1 equivalent of a strong base, e.g. an alkali hydride or alkali carbonate, to a solution of the starting compound in an anhydrous inert organic aprotic solvent, e.g. Hexamethylphosphoric triamide, dimethylformamide or dimethyl sulfoxide, and adding the compound of formula (II), preferably in equivalent amounts or in a slight excess in the same solvent.
  • a strong base e.g. an alkali hydride or alkali carbonate
  • an anhydrous inert organic aprotic solvent e.g. Hexamethylphosphoric triamide, dimethylformamide or dimethyl sulfoxide
  • the reaction is carried out at a temperature in the range from room temperature to about 100 ° C. In general, it is preferred to heat the reaction mixture, e.g. to 80 ° C to accelerate the reaction. Under these conditions, the reaction is usually completed within 2 hours.
  • the reaction mixture is worked up in a conventional manner, for example by solvent extraction.
  • the compounds of the formula (I) according to the invention with a basic imidazole radical can be converted into their pharmaceutically acceptable salts with weak organic acids in the customary manner.
  • Suitable acids are, for example, fumaric, oxalic, malonic, succinic, adipic, maleic, tartaric or citric acid.
  • the present invention also relates to the use of the new compounds of the formula (I) alone or in a mixture with other active substances in the form of conventional oral galenic compositions.
  • the compounds of the invention can be in the form of tablets or capsules, which are a unit dose of the compound together with diluents, such as Contain corn starch, calcium carbonate, dicalcium phosphate, alginic acid, lactose, magnesium stearate, Primogel or talc, orally administered.
  • the tablets are produced in a conventional manner by granulating the constituents and presses, and the capsules are produced by pouring them into hard gelatin capsules of a suitable size.
  • tablets or capsules can usually contain 5 to 150 mg of the active compound for oral administration up to three times a day.
  • the doctor will in any case determine the actual dosage which is most suitable for the individual patient, which can vary with the age, the mass and the response of the patient.
  • Example 1 A solution of 5 g (18.20 mol) of 5- [2- (1H-imidazol-1-yl) ethoxy] thiophene-2-carboxylic acid hydrochloride in 100 ml of hexamethylphosphoric triamide (HMPT) is removed at room temperature 2 g NaH (80% suspension) was added a little at a time with stirring, the temperature rising to about 40 ° C. To form the salt, the mixture was stirred at room temperature for 1 h and then a solution of 4.2 g (27.52 mmol) of 1-chloroethyl ethyl carbonate in 6 ml of HMPT were added dropwise at room temperature.
  • HMPT hexamethylphosphoric triamide
  • the reaction mixture is heated to 80 ° C. for 2% and then partitioned between ice water and ethyl acetate (EtOAc).
  • EtOAc ethyl acetate
  • the phases are separated, the aqueous phase is shaken three times with EtOAc and the organic phase is extracted twice with a saturated NaHC0 3 solution.
  • the EtOAc phase is shaken three times with 2N HC1; the HCl phase is neutralized with ice cooling and then exhaustively extracted with EtOAc.
  • the fumarate obtained is recrystallized from EtOAc, 4.0 g of 5- [2- (1H-imidazol-1-yl) ethoxy] thiophene-2-carboxylic acid 1-ethoxycarbonyloxyethyl ester fumarate (62.0% of the Theory), mp. 73-75 ° C, are obtained as colorless crystals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Indicating Or Recording The Presence, Absence, Or Direction Of Movement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne de nouveaux composés répondant à la formule générale (I), dans laquelle R en troisième et quatrième position représente hydrogène, méthyle, chlore ou brome et R2 représente alkyle C1-C10, cycloalkyle C3-C7 ou benzyle, leurs sels d'addition pharmaceutiquement acceptables avec des acides organiques faibles et leur procédé de préparation. Les composés répondant à la formule (I) sont des inhibiteurs de la synthétase de thromboxane.
EP92908327A 1991-04-04 1992-04-01 Nouveaux derives d'acide carboxylique de thiophene-2 et leur procede de preparation Expired - Lifetime EP0581797B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT716/91 1991-04-04
AT0071691A AT395425B (de) 1991-04-04 1991-04-04 Neue thiophen-2-carbonsaeurederivate und verfahren zu deren herstellung
PCT/AT1992/000044 WO1992017472A1 (fr) 1991-04-04 1992-04-01 Nouveaux derives d'acide carboxylique de thiophene-2 et leur procede de preparation

Publications (2)

Publication Number Publication Date
EP0581797A1 true EP0581797A1 (fr) 1994-02-09
EP0581797B1 EP0581797B1 (fr) 1997-07-23

Family

ID=3497929

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92890075A Pending EP0507763A1 (fr) 1991-04-04 1992-04-01 Dérivés d'acide thiophène-2-carboxylique et leur procédé de préparation
EP92908327A Expired - Lifetime EP0581797B1 (fr) 1991-04-04 1992-04-01 Nouveaux derives d'acide carboxylique de thiophene-2 et leur procede de preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP92890075A Pending EP0507763A1 (fr) 1991-04-04 1992-04-01 Dérivés d'acide thiophène-2-carboxylique et leur procédé de préparation

Country Status (15)

Country Link
US (1) US5352692A (fr)
EP (2) EP0507763A1 (fr)
JP (1) JPH06506208A (fr)
AT (2) AT395425B (fr)
AU (1) AU656772B2 (fr)
CA (1) CA2107662A1 (fr)
CZ (1) CZ280202B6 (fr)
DE (1) DE59208727D1 (fr)
DK (1) DK0581797T3 (fr)
ES (1) ES2104908T3 (fr)
FI (1) FI934184A (fr)
GR (1) GR3024594T3 (fr)
HU (1) HUT68476A (fr)
SK (1) SK106093A3 (fr)
WO (1) WO1992017472A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0891343A1 (fr) * 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
US8189397B2 (en) * 2008-01-08 2012-05-29 Spansion Israel Ltd Retention in NVM with top or bottom injection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126597A1 (de) * 1971-05-28 1972-12-14 Farbwerke Hoechst AG, vormals, Meister Lucius & Brüning, 6000 Frankfurt Aminothiophencarbonsäureester und Verfahren zu ihrer Herstellung
GB2065121A (en) * 1979-12-13 1981-06-24 Pfizer Ltd Isoquinoline Derivatives
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9217472A1 *

Also Published As

Publication number Publication date
FI934184A0 (fi) 1993-09-24
EP0581797B1 (fr) 1997-07-23
CA2107662A1 (fr) 1992-10-05
EP0507763A1 (fr) 1992-10-07
AT395425B (de) 1992-12-28
FI934184A (fi) 1993-09-24
SK106093A3 (en) 1994-08-10
DE59208727D1 (de) 1997-09-04
HU9302786D0 (en) 1993-12-28
ES2104908T3 (es) 1997-10-16
JPH06506208A (ja) 1994-07-14
WO1992017472A1 (fr) 1992-10-15
DK0581797T3 (da) 1998-02-02
US5352692A (en) 1994-10-04
HUT68476A (en) 1995-06-28
ATE155783T1 (de) 1997-08-15
AU656772B2 (en) 1995-02-16
ATA71691A (de) 1992-05-15
GR3024594T3 (en) 1997-12-31
CZ280202B6 (cs) 1995-11-15
AU1640292A (en) 1992-11-02
CZ9302002A3 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
EP0088274B1 (fr) 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments
DE3787346T2 (de) Dihydropyridin-Derivate, ihre Herstellung und ihre Verwendung.
DE2933649C2 (fr)
DE69014351T2 (de) Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE3788385T2 (de) Pyrimidin-Derivate.
DE3026201C2 (fr)
DE3788982T2 (de) Trans-6-[2-(N-heteroaryl)-3,5-disubstituiertes)pyrazol-4-yl)-ethyl] oder -ethenyl]tetrahydro-4-hydroxypyran-2-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE2651572C2 (de) Aminoalkohole, Verfahren zu deren Herstellung sowie diese enthaltende pharmazeutische Zubereitungen
DE2905811C2 (fr)
EP0028765B1 (fr) Dérivés de l'alkylurée pour le traitement des maladies du métabolisme des graisses; procédé pour leur préparation, leur application dans des médicaments pour le traitement des altérations du métabolisme des graisses, médicaments les contenant, procédé pour leur préparation, ainsi que quelques dérivés de l'alkylurée
EP0071059B1 (fr) 6-(5-(Oméga(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tétrahydropyridazines et leurs sels d'addition acides, procédé pour leur fabrication et composés pharmaceutiques les contenant
DE3852332T2 (de) 4-Thiochinazolin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellungen.
DE3006671A1 (de) Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
DE69002338T2 (de) Pyrrolidin-Derivate und ihre pharmazeutische Verwendung.
EP0008645A1 (fr) Alcoxyphénylpyrrolidones, procédé pour leur préparation et médicaments les contenant
DE69106323T2 (de) Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen.
EP0581797B1 (fr) Nouveaux derives d'acide carboxylique de thiophene-2 et leur procede de preparation
EP0109381B1 (fr) Dérivés de l'acide thiophène-2-carboxylique et procédé pour leur préparation
DE2819873C2 (fr)
EP1444234A2 (fr) Pyrazolopyrimidinones deuterees et medicaments contenant ces composes
AT391316B (de) Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0439796B1 (fr) Indolylpropanols, leur procédé de préparation, leur utilisation et préparations les contenant
DE2943326C2 (fr)
DE2922070A1 (de) Hydantoine und ihre verwendung in pharmazeutischen zubereitungen
EP0965591B1 (fr) Procédé pour la préparation de (S)-3-methyl-1-(2-piperidino-phényl-1-butylamine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

XX Miscellaneous (additional remarks)

Free format text: VERBUNDEN MIT 92890075.2/0507763 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 17.05.95.

17Q First examination report despatched

Effective date: 19950714

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 155783

Country of ref document: AT

Date of ref document: 19970815

Kind code of ref document: T

XX Miscellaneous (additional remarks)

Free format text: VERBUNDEN MIT 92890075.2/0507763 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 17.05.95.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 59208727

Country of ref document: DE

Date of ref document: 19970904

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

ITF It: translation for a ep patent filed

Owner name: NOTARBARTOLO & GERVASI S.P.A.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2104908

Country of ref document: ES

Kind code of ref document: T3

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19971006

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3024594

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19971015

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19980317

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 19980318

Year of fee payment: 7

Ref country code: MC

Payment date: 19980318

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19980319

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19980323

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19980324

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19980326

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19980416

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19980417

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19980423

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19980429

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19980430

Year of fee payment: 7

Ref country code: LU

Payment date: 19980430

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19980630

Year of fee payment: 7

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19981113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990401

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990401

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990430

BERE Be: lapsed

Owner name: LAEVOSAN-G.M.B.H.

Effective date: 19990430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19990401

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991231

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19991101

EUG Se: european patent has lapsed

Ref document number: 92908327.7

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19991031

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050401